Loading...

We've got a brand new version of Simply Wall St! Try it out

KBL Merger IV

Nasdaq:KBLM.U
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KBLM.U
Nasdaq
$45M
Market Cap
  1. Home
  2. US
  3. Diversified Financials
Company description

KBL Merger Corp. IV is a private equity firm specializing in acquisition, buyout, PIPES and secondaries investments. The last earnings update was 7 days ago. More info.


Add to Portfolio Compare Print
  • KBL Merger IV is a fund or ETF! Currently our data availability for these is poor, we only recommend using them as part of a portfolio.
KBLM.U Share Price and Events
7 Day Returns
0%
NasdaqCM:KBLM.U
1%
US Capital Markets
0.7%
US Market
1 Year Returns
-
NasdaqCM:KBLM.U
8.6%
US Capital Markets
13.7%
US Market
KBLM.U Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
KBL Merger IV (KBLM.U) 0% - - - - -
US Capital Markets 1% 5.5% 7.4% 8.6% 34.5% 59.9%
US Market 0.7% 4.7% 6.1% 13.7% 39.2% 44.5%
1 Year Return vs Industry and Market
  • No trading data on KBLM.U.
  • No trading data on KBLM.U.

KBLM.U Value

 Is KBL Merger IV undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of KBL Merger IV to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for KBL Merger IV.

NasdaqCM:KBLM.U Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Excess Returns Model
Stable EPS Median Return on Equity from the past 5 years.
= Stable Book Value * Return on Equity
= $1.19 * 10.7%
$0.13
Book Value of Equity per Share Median Book Value from the past 5 years. $1.19
Discount Rate (Cost of Equity) See below 7.8%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:KBLM.U
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Capital Markets Unlevered Beta Simply Wall St/ S&P Global 0.75
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.753 (1 + (1- 21%) (4.47%))
0.852
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.85
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.852 * 5.96%)
7.81%

Discounted Cash Flow Calculation for NasdaqCM:KBLM.U using Excess Returns Model Model

The calculations below outline how an intrinsic value for KBL Merger IV is arrived at using the Excess Return Model. This approach is used for finance firms where free cash flow is difficult to estimate.

In the Excess Return Model the value of a firm can be written as the sum of capital invested currently in the firm and the present value of excess returns that the firm expects to make in the future.

The model is sensitive to the Return on Equity of the company versus the Cost of Equity, how these are calculated is detailed below the main calculation.

Note the calculations below are per share.

See our documentation to learn about this calculation.

NasdaqCM:KBLM.U Value of Excess Returns
Calculation Result
Excess Returns = (Stable Return on equity – Cost of equity) (Book Value of Equity per share)
= (10.7% – 7.81%) * $1.19)
$0.03
Terminal Value of Excess Returns = Excess Returns / (Cost of Equity - Expected Growth Rate)
= $0.03 / (7.81% - 2.73%)
$0.68
Value of Equity = Book Value per share + Terminal Value of Excess Returns
= $1.19 + $0.68
$1.87
NasdaqCM:KBLM.U Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in NasdaqCM:KBLM.U represents 1.02103x of NasdaqCM:KBLM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.02103x
Value per Share
(Listing Adjusted, USD)
= Value per Share (USD) x Listing Adjustment Factor
= $ 1.87 x 1.02103
$1.91
Value per share (USD) From above. $1.91
Current discount Discount to share price of $10.74
= -1 x ($10.74 - $1.91) / $1.91
-463%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of KBL Merger IV is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for KBL Merger IV's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are KBL Merger IV's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:KBLM.U PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $0.13
NasdaqCM:KBLM Share Price ** NasdaqCM (2019-10-28) in USD $10.52
United States of America Capital Markets Industry PE Ratio Median Figure of 88 Publicly-Listed Capital Markets Companies 37.79x
United States of America Market PE Ratio Median Figure of 2,924 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of KBL Merger IV.

NasdaqCM:KBLM.U PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:KBLM Share Price ÷ EPS (both in USD)

= 10.52 ÷ 0.13

82.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • KBL Merger IV is overvalued based on earnings compared to the US Capital Markets industry average.
  • KBL Merger IV is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does KBL Merger IV's expected growth come at a high price?
Raw Data
NasdaqCM:KBLM.U PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 82.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Capital Markets Industry PEG Ratio Median Figure of 38 Publicly-Listed Capital Markets Companies 2.02x
United States of America Market PEG Ratio Median Figure of 2,038 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for KBL Merger IV, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on KBL Merger IV's assets?
Raw Data
NasdaqCM:KBLM.U PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $1.16
NasdaqCM:KBLM Share Price * NasdaqCM (2019-10-28) in USD $10.52
United States of America Capital Markets Industry PB Ratio Median Figure of 155 Publicly-Listed Capital Markets Companies 6.4x
United States of America Market PB Ratio Median Figure of 5,086 Publicly-Listed Companies 1.76x
NasdaqCM:KBLM.U PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:KBLM Share Price ÷ Book Value per Share (both in USD)

= 10.52 ÷ 1.16

9.05x

* Primary Listing of KBL Merger IV.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • KBL Merger IV is overvalued based on assets compared to the US Capital Markets industry average.
X
Value checks
We assess KBL Merger IV's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Capital Markets industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Capital Markets industry average (and greater than 0)? (1 check)
  5. KBL Merger IV has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

KBLM.U Future Performance

 How is KBL Merger IV expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as KBL Merger IV has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
5.3%
Expected Capital Markets industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is KBL Merger IV expected to grow at an attractive rate?
  • Unable to compare KBL Merger IV's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare KBL Merger IV's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare KBL Merger IV's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:KBLM.U Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Capital Markets Industry Earnings Growth Rate Market Cap Weighted Average 5.3%
United States of America Capital Markets Industry Revenue Growth Rate Market Cap Weighted Average 3.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:KBLM.U Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:KBLM.U Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 -1 1
2019-06-30 -1 1
2019-03-31 -1 1
2018-12-31 -1 1
2018-09-30 -1 1
2018-06-30 -1 1
2018-03-31 -1 0
2017-12-31 0 0
2016-12-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if KBL Merger IV is high growth as no earnings estimate data is available.
  • Unable to determine if KBL Merger IV is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:KBLM.U Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from KBL Merger IV Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:KBLM.U Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 0.13
2019-06-30 0.21
2019-03-31 0.27
2018-12-31 0.25
2018-09-30 0.18
2018-06-30 0.13
2018-03-31 0.08
2017-12-31 0.04
2016-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if KBL Merger IV will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. KBL Merger IV's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Diversified Financials companies here
  2. KBL Merger IV's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess KBL Merger IV's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
KBL Merger IV has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

KBLM.U Past Performance

  How has KBL Merger IV performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare KBL Merger IV's growth in the last year to its industry (Capital Markets).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient data to establish if KBL Merger IV's year on year earnings growth rate was positive over the past 5 years.
  • KBL Merger IV's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • KBL Merger IV's 1-year earnings growth is negative, it can't be compared to the US Capital Markets industry average.
Earnings and Revenue History
KBL Merger IV's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from KBL Merger IV Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:KBLM.U Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 0.54 0.96
2019-06-30 0.88 0.87
2019-03-31 1.10 0.73
2018-12-31 1.04 0.60
2018-09-30 0.77 0.55
2018-06-30 0.53 0.55
2018-03-31 0.33 0.45
2017-12-31 0.12 0.34
2016-12-31 -0.01 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • KBL Merger IV has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • It is difficult to establish if KBL Merger IV has efficiently used its assets last year compared to the US Capital Markets industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if KBL Merger IV improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess KBL Merger IV's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Capital Markets industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
KBL Merger IV has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

KBLM.U Health

 How is KBL Merger IV's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up KBL Merger IV's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • KBL Merger IV's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • KBL Merger IV's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of KBL Merger IV's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from KBL Merger IV Company Filings, last reported 1 month ago.

NasdaqCM:KBLM.U Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 5.00 2.01 0.84
2019-06-30 5.00 1.37 0.11
2019-03-31 5.00 0.94 0.13
2018-12-31 5.00 0.20 0.27
2018-09-30 5.00 0.40 0.52
2018-06-30 5.00 0.39 0.54
2018-03-31 5.00 0.08 0.34
2017-12-31 5.00 0.05 0.43
2016-12-31 0.02 0.14 0.07
  • KBL Merger IV's level of debt (40.1%) compared to net worth is high (greater than 40%).
  • Unable to establish if KBL Merger IV's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on KBL Merger IV's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess KBL Merger IV's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. KBL Merger IV has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

KBLM.U Dividends

 What is KBL Merger IV's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from KBL Merger IV dividends.
If you bought $2,000 of KBL Merger IV shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate KBL Merger IV's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate KBL Merger IV's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:KBLM.U Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Capital Markets Industry Average Dividend Yield Market Cap Weighted Average of 43 Stocks 2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as KBL Merger IV has not reported any payouts.
  • Unable to verify if KBL Merger IV's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of KBL Merger IV's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as KBL Merger IV has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess KBL Merger IV's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can KBL Merger IV afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. KBL Merger IV has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

KBLM.U Management

 What is the CEO of KBL Merger IV's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marlene Krauss
AGE 73
TENURE AS CEO 3.2 years
CEO Bio

Dr. Marlene R. Krauss, M.D., has been Chief Executive Officer at KBL Merger Corp. IV since September 7, 2016. Dr. Krauss serves as a Managing Director, the Chief Executive Officer, Secretary and a Member of the Board of Directors of KBL Healthcare Ventures. Dr. Krauss also holds these positions at KBL Healthcare, L.P. Previously CEO and Chairman of three KBL SPACs. She co-founded the firm in 1991 and has over ten years clinical experience as a physician and many years experience in healthcare focused public and private equity investing. Dr. Krauss has been the Chief Executive Officer and Secretary at KBL Healthcare Acquisition Corp. II since its inception on December 9, 2004 until March 2007 and Chairman of the Board since March 2007. She co-founded Lumenos Inc in June 1999 and has served as a member of its Board of Directors since its formation. Dr. Krauss has also been the Managing Member and President at KBL Healthcare Management Inc. since November 1998. During this time, she co-founded or has served on the board of directors of several of KBL Healthcare Management’s portfolio companies. Dr. Krauss also co-founded Cambridge Heart, Inc. and served as a Chairperson of the Board until September 1997 and Vice Chairperson from 1994 to 1996. From April 1993 to August 1994, she served as a Chairperson and Chief Executive Officer at KBL I. Dr. Krauss co-founded and was the Chairperson and Chief Executive Officer at KBL Healthcare Acquisition Corporation. She also co-founded and led the initial financing for Candela Corporation and Summit Autonomous Inc. From 1986 to 1989, Dr. Krauss was a Clinical Instructor in Ophthalmology at Cornell Medical College and was engaged in the private practice of ophthalmology. She served as Director of CardioFocus, Inc. She has been Director at KBL Merger Corp. IV since September 7, 2016. She serves on the Board of Directors of Gynétics, Prolong Pharmaceuticals, Summit Technology and PneumRx, Inc. Dr. Krauss served as a Director of APS Healthcare, Inc. since 1994. She is director of the Harvard Business School Board of Dean’s Advisors. She was a Director of Concord Health Group Inc until February 1996. Dr. Krauss is also a Director at Harvard Business School Club of Greater New York. Dr. Krauss is also a Founding Member of the President's Council of Cornell Women and the Harvard Business School Women's Association. She is the recipient of the 1996 Harvard Business School Alumni Achievement Award. Dr. Krauss is a Board-Certified Ophthalmologist with a specialty in Vitreo-Retinal Surgery. From 1979 to 1986, she completed her clinical training at the Beth Israel Hospital, the Harvard Surgical Service at the Deaconess Hospital, the Mount Sinai Hospital and New York Hospital. Dr. Krauss was the second female M.B.A. graduate to have won this prestigious award, which has been granted since 1968. She completed her training as a vitreoretinal surgeon at New York Hospital in 1985, where she has served as Clinical Instructor of Ophthalmology. She is a Board Certified Ophthalmologist. She is Fellow of the American Academy of Ophthalmology. Dr. Krauss has many years of experience in acquiring, growing and selling more than 20 companies in healthcare services, pharmaceuticals and medical devices. She spent many years experience as an ophthalmic surgeon. Dr. Krauss received an M.D. degree from Harvard Medical School in 1979. She received a B.A. degree in 1965 from Cornell University’s College of Arts and Sciences and an M.B.A. degree from Harvard Graduate School of Business Administration in 1967.

CEO Compensation
  • Insufficient data for Marlene to compare compensation growth.
  • Insufficient data for Marlene to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team

Marlene Krauss

TITLE
CEO & Director
AGE
73
TENURE
3.2 yrs

Joe Williamson

TITLE
COO & Director
AGE
66
TENURE
2.4 yrs

JP Garnier

TITLE
Scientific Advisor
AGE
72

Mike Weisfeldt

TITLE
Scientific Advisor

Phyllis Gardner

TITLE
Scientific Advisor
AGE
68

Roy Geronemus

TITLE
Scientific Advisor
AGE
66

Ellen Marram

TITLE
Special Advisor
AGE
72
Board of Directors Tenure

Average tenure and age of the KBL Merger IV board of directors in years:

2.4
Average Tenure
66
Average Age
  • The average tenure for the KBL Merger IV board of directors is less than 3 years, this suggests a new board.
Board of Directors

George Hornig

TITLE
Independent Chairman of the Board
AGE
65
TENURE
2.4 yrs

Marlene Krauss

TITLE
CEO & Director
AGE
73
TENURE
3.2 yrs

Joe Williamson

TITLE
COO & Director
AGE
66
TENURE
2.4 yrs

Sherrill Neff

TITLE
Independent Director
AGE
67
TENURE
2.4 yrs

Andrew Sherman

TITLE
Independent Director
AGE
49
TENURE
2.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess KBL Merger IV's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. KBL Merger IV has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

KBLM.U News

Simply Wall St News

KBLM.U Company Info

Description

KBL Merger Corp. IV is a private equity firm specializing in acquisition, buyout, PIPES and secondaries investments. The firm seeks to invest in healthcare or the healthcare-related wellness industry. In healthcare services the firm seeks to invest in outpatient care, physician practices, behavioral health and payor services. In pharma services the firm seeks to invest in outsourced services, contract research and generics / OTC. In health IT the firm seeks to invest in EMR / HER, revnue cycle management, telemedicine and care management. In minimal reimbursement risk the firm focuses on retail healthcare, wellness and preventative care. In devices and diagnostics the firm focuses on medical devices, diagnostics, genetic testing and lab tools. The firm typically invests in firms located in the United States. The firm seeks to invest in firms with valuation between $200 million to $700 million and EBITDA between $20 million to $70 million. The firms invest in firms with enterprise value $200 million to $700 million. The firm seeks to take majority stakes. KBL Merger Corp. IV was founded in 2016 and is New York, New York with an additional office in Newark, Delaware.

Details
Name: KBL Merger Corp. IV
KBLM.U
Exchange: NasdaqCM
Founded: 2016
$44,860,341
4,264,291
Website: http://www.kblmerger.com
Address: KBL Merger Corp. IV
150 West 56th Street,
Suite 5901,
New York,
New York, 10019,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM KBLM Common Stock Nasdaq Capital Market US USD 27. Jun 2017
NasdaqCM KBLM.U Units Nasdaq Capital Market US USD 02. Jun 2017
Number of employees
Current staff
Staff numbers
2
KBL Merger IV employees.
Industry
Asset Management and Custody Banks
Diversified Financials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/19 00:54
End of day share price update: 2019/10/28 00:00
Last earnings filing: 2019/11/12
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.